These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 17069058)

  • 21. [Treatment of early Parkinson's disease].
    Delvaux V; Moonen G; Garraux G
    Rev Med Liege; 2009 Apr; 64(4):228-32. PubMed ID: 19514544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cerebrovascular and antiserotoninergic activity of the combination of tropoxin and mexidol].
    Gorbunov AA; Gan'shina TS; Turilova AI; Mirzoian RS
    Eksp Klin Farmakol; 2011; 74(8):23-7. PubMed ID: 22232910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the hook of Uncaria rhynchophylla on neurotoxicity in the 6-hydroxydopamine model of Parkinson's disease.
    Shim JS; Kim HG; Ju MS; Choi JG; Jeong SY; Oh MS
    J Ethnopharmacol; 2009 Nov; 126(2):361-5. PubMed ID: 19703534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of emoxipine, reamberine and mexidol on neuropathic symptoms and a systolic function of the left ventricular myocardium in patients with diabetes mellitus and diabetic foot syndrome].
    Volchegorskiĭ IA; Moskvicheva MG; Chashchina EN
    Ter Arkh; 2005; 77(10):10-5. PubMed ID: 16320677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Neuronal activities in the ventrolateral thalamus and basal ganglia in relation to Parkinson's disease].
    Wang J; Zhuang P; Li YJ
    Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(15):1021-6. PubMed ID: 16784702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of mexidol on efficacy of traditional therapy of sick sinus syndrome in adolescents].
    Balykova LA
    Eksp Klin Farmakol; 2003; 66(5):25-7. PubMed ID: 14650210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current pharmacotherapy of Parkinson's disease].
    Takáts A
    Orv Hetil; 2000 Mar; 141(10):483-8. PubMed ID: 10750400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effects of mexidol in pain syndromes].
    Danilova ED; Grafova VN; Voronina TA; Reshetniak VK
    Eksp Klin Farmakol; 1995; 58(3):17-20. PubMed ID: 7663286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficiency of mexidol in patients with endocrine polyneuropathy].
    Kuznetsova EB; Sholomov II; Gerasimov SV; Salina EA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(4):97-9. PubMed ID: 24874328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The use of mexidol in psychiatric practice].
    Kosenko VG; Karagezian EA; Luneva LV; Smolenko LF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(6):38-41. PubMed ID: 16841482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of alpha-lipoic acid and mexidol on neuro- and the affective status in patients at early stages of diabetic foot syndrome].
    Volchegorskiĭ IA; Alekseev MN; Volchegorskaia MI; Rassokhina LM
    Klin Med (Mosk); 2008; 86(10):52-9. PubMed ID: 19069461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The effect of semax and mexidol on the course of acute pancreatitis in rats].
    Ivanov IuV; Iasnetsov VV
    Eksp Klin Farmakol; 2000; 63(1):41-4. PubMed ID: 10763109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine receptor agonists in the treatment of advanced Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S54-7. PubMed ID: 20123558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Myometry revealed medication-induced decrease in resting skeletal muscle stiffness in Parkinson's disease patients.
    Marusiak J; Jaskólska A; Koszewicz M; Budrewicz S; Jaskólski A
    Clin Biomech (Bristol, Avon); 2012 Jul; 27(6):632-5. PubMed ID: 22365901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The neuroprotective therapy of outpatient treatment of chronic cerebral ischemia].
    Berezhnaya SV; Yakupov EZ
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(6):48-52. PubMed ID: 26356397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Central dopaminergic D1 agonists and treatment of Parkinson disease].
    Soubrouillard C; Lombardo C; Rascol O; Bruguerolle B; Blin O
    Therapie; 1997; 52(6):527-34. PubMed ID: 9734104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dihydroergocryptine in the treatment of Parkinson's disease.
    Bonuccelli U; D'Antonio P; D'Avino C; Piccini P; Muratorio A
    J Neural Transm Suppl; 1995; 45():239-45. PubMed ID: 8748631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acetyl-L-carnitine and α-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy.
    Zaitone SA; Abo-Elmatty DM; Shaalan AA
    Pharmacol Biochem Behav; 2012 Jan; 100(3):347-60. PubMed ID: 21958946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.